Abstract
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by social communication deficits and repetitive behaviors, with growing evidence highlighting the role of the gut microbiome in its pathophysiology. Studies suggest that ASD individuals exhibit gut dysbiosis, marked by an increased abundance of Clostridium and Desulfovibrio species and reduced levels of beneficial bacteria such as Bifidobacterium and Lactobacillus, potentially contributing to neuroinflammation and ASD-related behaviors. Maternal and environmental factors, including immune activation, obesity, cesarean section deliveries, and early antibiotic exposure, may further predispose children to ASD by altering early microbial colonization and gut-brain communication. Gastrointestinal (GI) disturbances are prevalent in ASD, with microbial imbalances potentially exacerbating symptoms through immune and metabolic pathways. Microbiota-based therapeutic strategies, including probiotics, prebiotics, dietary interventions, and fecal microbiota transplantation (FMT), have shown potential in alleviating both GI and behavioral symptoms. Notably, Microbiota Transfer Therapy (MTT) has demonstrated long-term benefits, reinforcing the therapeutic potential of gut microbiota modulation. However, inconsistencies in study methodologies, small sample sizes, and the lack of standardized treatment protocols necessitate further large-scale clinical trials. Future research should focus on identifying specific microbial signatures associated with ASD, optimizing microbiota-targeted therapies, and exploring personalized treatment approaches to improve ASD management.